Astellas Engineered Small Molecules U.K. Ltd. develops small‑molecule therapeutics, focusing on mito Sign up to read more
Profile updated Aug 2026
| Allotment | Filed | Share Class | Round Size | Round Type |
|---|---|---|---|---|
2025-01-27 | £4.0M |
| Shareholder | Share class | Shares | Holding |
|---|---|---|---|
| ASTELLAS PHARMA EUROPE LTD.CORP | GROWTH, ORDINARY | 4,912,933 | 100.0% |
Companies with the most similar business descriptions.
Capital raised per employee divides the equity ASTELLAS ENGINEERED SMALL MOLECULES U.K. LIMITED raised in the last six months by the headcount in its most recent filed accounts. It is a rough read on how capital-intensive the business is: a high figure means the company is raising a lot relative to the number of people it employs, which is typical of hardware, biotech and other research-heavy businesses. Headcount comes from annual accounts and so lags the funding date, often by a year or more.
These are the directors and secretaries who have left ASTELLAS ENGINEERED SMALL MOLECULES U.K. LIMITED. A resignation is filed with Companies House on form TM01 and the date below is the date the officer's appointment ended, not the date it was filed. Departures matter for reading a company's history: a founder leaving shortly after a funding round, or several directors resigning at once, is often the visible trace of a change of control or a restructure.